MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
MiNK Therapeutics (NASDAQ: INKT) announced two poster presentations at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston, Texas, from November 6-10, 2024. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR.
The first presentation, titled 'AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response,' is scheduled for Friday, November 8th (Abstract Number: 753).
The second presentation, 'PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME,' will take place on Saturday, November 9th (Abstract Number: 374).
MiNK Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases.
MiNK Therapeutics (NASDAQ: INKT) ha annunciato due presentazioni di poster durante il 29° Congresso Annuale della Society for Immunotherapy of Cancer a Houston, Texas, dal 6 al 10 novembre 2024. Le presentazioni mostreranno nuovi dati preclinici dai programmi iNKT cell di MiNK, agenT-797 e PRAME-TCR.
La prima presentazione, intitolata 'La terapia cellulare con AgenT-797 può essere combinata con inibitori del checkpoint immunitario di nuova generazione (ICI) e/o engagers bi-specifici per migliorare la risposta antitumorale,' è prevista per venerdì 8 novembre (Numero Abstract: 753).
La seconda presentazione, 'Terapia cellulare PRAME-TCR iNKT: Opportunità per una terapia oncologica di prima classe, pronta all'uso, mirata a PRAME,' si svolgerà sabato 9 novembre (Numero Abstract: 374).
MiNK Therapeutics è un'azienda biofarmaceutica in fase clinica che si concentra sullo sviluppo di terapie cellulari allogeniche, pronte all'uso, con cellule T natural killer invarianti (iNKT) per il cancro e altre malattie mediate dal sistema immunitario.
MiNK Therapeutics (NASDAQ: INKT) anunció dos presentaciones de póster en el 29º Congreso Anual de la Sociedad de Inmunoterapia del Cáncer en Houston, Texas, del 6 al 10 de noviembre de 2024. Las presentaciones mostrarán nuevos datos preclínicos de los programas de células iNKT de MiNK, agenT-797 y PRAME-TCR.
La primera presentación, titulada 'La terapia celular con AgenT-797 puede combinarse con inhibidores de puntos de control inmunitario de nueva generación (ICI) y/o engagers bispecíficos para mejorar la respuesta anticancerígena,' está programada para el viernes 8 de noviembre (Número de Resumen: 753).
La segunda presentación, 'Terapia celular PRAME-TCR iNKT: Oportunidad para una terapia clínica lista para usar para tumores sólidos que apunten a PRAME,' tendrá lugar el sábado 9 de noviembre (Número de Resumen: 374).
MiNK Therapeutics es una empresa biofarmacéutica en etapa clínica que se centra en el desarrollo de terapias con células T natural killer invariantes (iNKT) alogénicas, listas para usar, para el cáncer y otras enfermedades mediadas por el sistema inmunológico.
미NK 테라퓨틱스 (NASDAQ: INKT)는 텍사스 휴스턴에서 2024년 11월 6일부터 10일까지 열리는 암 면역요법 학회의 제29회 연례 회의에서 두 가지 포스터 발표를 발표했습니다. 이 발표는 미NK의 iNKT 세포 프로그램인 agenT-797 및 PRAME-TCR의 새로운 전임상 데이터를 보여줄 것입니다.
첫 번째 발표는 'AgenT-797 세포 요법은 차세대 면역 체크포인트 억제제(ICI) 및/또는 이중 특이적 항체와 결합하여 항암 반응을 개선할 수 있다'라는 제목으로 11월 8일 금요일에 예정되어 있습니다 (초록 번호: 753).
두 번째 발표는 'PRAME-TCR iNKT 세포 요법: PRAME을 타겟으로 하는 최고의 오프더셸프 고형종양 요법의 기회'라는 제목으로 11월 9일 토요일에 진행됩니다 (초록 번호: 374).
미NK 테라퓨틱스는 암과 기타 면역 매개 질병을 위해 알로겐적인 오프더셸프 불변 자연살해 세포(iNKT) 요법 개발에 중점을 둔 임상 단계의 생물 제약 회사입니다.
MiNK Therapeutics (NASDAQ: INKT) a annoncé deux présentations d'affiches lors du 29e Congrès Annuel de la Société pour l'Immunothérapie du Cancer à Houston, Texas, du 6 au 10 novembre 2024. Les présentations mettront en avant de nouvelles données précliniques des programmes de cellules iNKT de MiNK, agenT-797 et PRAME-TCR.
La première présentation, intitulée 'La thérapie cellulaire AgenT-797 peut être combinée avec des inhibiteurs de point de contrôle immunitaire de nouvelle génération (ICI) et/ou des agents bi-spécifiques pour améliorer la réponse anticancéreuse,' est prévue pour le vendredi 8 novembre (Numéro d'Abstract : 753).
La deuxième présentation, 'Thérapie cellulaire PRAME-TCR iNKT : Opportunité pour une thérapie de pointe prête à l'emploi contre les tumeurs solides ciblant PRAME,' aura lieu le samedi 9 novembre (Numéro d'Abstract : 374).
MiNK Therapeutics est une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies cellulaires allogéniques, prêtes à l'emploi, avec des cellules T natural killer invariantes (iNKT) pour le cancer et d'autres maladies médiées par le système immunitaire.
MiNK Therapeutics (NASDAQ: INKT) gab zwei Posterpräsentationen auf dem 29. Jahreskongress der Society for Immunotherapy of Cancer in Houston, Texas, vom 6. bis 10. November 2024 bekannt. Die Präsentationen werden neue präklinische Daten aus MiNKs iNKT-Zellprogrammen, agenT-797 und PRAME-TCR, präsentieren.
Die erste Präsentation mit dem Titel 'AgenT-797 Zelltherapie kann mit neuartigen Immun-Checkpoint-Hemmern (ICI) und/oder bispezifischen Engagern kombiniert werden, um die anti-tumorale Reaktion zu verbessern,' ist für Freitag, den 8. November, geplant (Abstract-Nr.: 753).
Die zweite Präsentation mit dem Titel 'PRAME-TCR iNKT Zelltherapie: Gelegenheit für eine erstklassige, sofort einsetzbare Therapie bei soliden Tumoren, die PRAME anvisiert,' findet am Samstag, den 9. November, statt (Abstract-Nr.: 374).
MiNK Therapeutics ist ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von allogenen, sofort einsetzbaren Zelltherapien mit invarianten natürlichen Killer-T-Zellen (iNKT) für Krebs und andere immunvermittelte Krankheiten spezialisiert hat.
- None.
- None.
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 29th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK’s iNKT cell programs, agenT-797 and PRAME-TCR.
Presentation Details
Title: AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response
Abstract Number: 753
Date: Friday, November 8th
Title: PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME
Abstract Number: 374
Session Date: Saturday, November 9th
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
When and where will MiNK Therapeutics present its iNKT cell program data?
What are the titles of MiNK Therapeutics' poster presentations at SITC 2024?
What type of data will MiNK Therapeutics (INKT) present at SITC 2024?
What is the focus of MiNK Therapeutics' research?
